At the International AIDS Society meeting this year, a young woman from South Africa spoke. She is the first Black woman from ...

In the mid-1990s, clinicians treating people with HIV began to notice a syndrome characterized by loss of limb fat, facial ...

South Africa is among the first countries in line to receive doses of lenacapavir, the six-monthly injection for HIV prevention. According to national health department projections, the country could ...

CVS Health, one of the nation’s largest pharmacy benefit manager companies that play a lead role in deciding which drugs are ...

Gilead Sciences (($GILD)) announced an update on their ongoing clinical study. Gilead Sciences is currently recruiting participants for a clinical ...

Gilead exceeded market expectations in the second quarter, reporting earnings per share of $2.01 on revenue of $7.08 billion. Profitability metrics impressed with a 21.86% margin and a return on ...

Biotech investors tend to focus on small-cap companies in search of the next big breakthrough. Still, one established player ...

The Gilead HIV prevention shot , called Yevtugo, is highly effective, but its list price is $28, 218 a year in the U.S.

Approved in June for people at high risk of HIV, Yeztugo was shown to be nearly 100% effective at preventing infection in ...

The owner of the U.S.' largest pharmacy benefit manager is declining to cover Gilead Sciences’ long-acting HIV prevention ...

CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's ...

In people with HIV infection, new-onset diabetes is independently predicted by higher leukocyte counts — mostly within the ...